Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer

Author(s): Toshiyoshi Fujiwara, Shunsuke Kagawa, Hiroshi Tazawa

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 9 , 2012

Become EABM
Become Reviewer


Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis through the maintenance of telomeres, and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector, in which the hTERT promoter element drives expression of E1 genes, OBP-301 (Telomelysin). Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication and oncolytic cell death. OBP-301 alone exhibited substantial antitumor effects both in animal models and in clinical trials; data regarding combination therapy with OBP-301 and chemotherapeutic agents are preliminary but encouraging. This article reviews synergistic interaction of virotherapy and chemotherapy, and illustrates the potential application for the treatment of human cancer.

Keywords: Telomerase, adenovirus, virotherapy, docetaxel, histon deacetylase inhibitor, gemcitabine, neoplastic disease, viral genes

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 13 June, 2012
Page: [1809 - 1816]
Pages: 8
DOI: 10.2174/138920112800958887
Price: $65

Article Metrics

PDF: 9